Skip to main content

Qulipta Side Effects

Generic name: atogepant

Medically reviewed by Philip Thornton, DipPharm. Last updated on Sep 17, 2022.

Note: This document contains side effect information about atogepant. Some dosage forms listed on this page may not apply to the brand name Qulipta.

Applies to atogepant: oral tablet.

Serious side effects of Qulipta

Along with its needed effects, atogepant (the active ingredient contained in Qulipta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Other side effects of Qulipta

Some side effects of atogepant may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

  • Decreased appetite
  • decreased weight

For Healthcare Professionals

Applies to atogepant: oral tablet.

General

The more commonly reported adverse reactions have included nausea, constipation, and fatigue.[Ref]

Gastrointestinal

Common (1% to 10%): Nausea, constipation

Metabolic

Common (1% to 10%): Decreased appetite, weight loss

Weight loss of greater than 7% of body weight was reported for 3.8% of patients receiving 10 mg/day, 3.2% for 30 mg/day, and 4.9% for patients receiving 60 mg/day (compared to 2.8% for placebo).

Hepatic

Transaminase elevations greater than 3 times the upper limit of normal (3 x ULN) were reported similarly for patients receiving this drug and those receiving placebo (1% vs 1.8%). Temporally associated cases of transaminase elevations were reported with use of this drug; they were asymptomatic and resolved within 8 weeks of discontinuation.[Ref]

Common (1% to 10%): Liver enzyme elevations[Ref]

Nervous system

Common (1% to 10%): Fatigue/somnolence

Frequently asked questions

References

1. "Product Information. Qulipta (atogepant)." AbbVie US LLC (2021):

2. Boinpally R, Jakate A, Butler M, Borbridge L< Periclou A "Single-dose pharmacokinetics and safety of atogepant in adults with hepatic impairment: results from an open-label, phase 1 trial." Clin Pharmacol Drug Dev 10 (2021): 726-33

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.